Wire · opportunities
GLP-1 ad war spills into court as Novo Nordisk alleges Eli Lilly ignores science
◆ Sectors
◆ Geography
◆ Source
◆ Verified
Fusion42 · 22 July 2026 · Fusion42 review
Novo Nordisk has sued Eli Lilly, alleging its Zepbound advertisements misleadingly compare low doses of Novo's Wegovy to Zepbound's highest dose, cherry-picking outdated clinical trial data to claim superiority. Eli Lilly defends its ads as based on the only head-to-head trial and states it discloses the dose comparison limitation.
This Wire brief sits within Fusion42's coverage of Digital Health.
◆ ◆ The Wire takeaway
If you're selling a GLP-1 competitor or building distribution in weight loss, Eli Lilly's marketing playbook just became litigable territory - and the court will decide what dose comparisons count as fair game. Watch this case: a win for Novo sets the standard for how claims get made in this market.
◆ Coverage
1 source · 22 Jul 2026
◆ Related on Wire
◆ Topics